Zymergen (NASDAQ:ZY – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Zymergen to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.
This table compares Zymergen and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Zymergen and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zymergen presently has a consensus target price of $6.75, indicating a potential upside of 287.93%. As a group, “Commercial physical research” companies have a potential upside of 29.86%. Given Zymergen’s higher possible upside, research analysts plainly believe Zymergen is more favorable than its competitors.
Insider and Institutional Ownership
48.8% of Zymergen shares are held by institutional investors. Comparatively, 56.5% of shares of all “Commercial physical research” companies are held by institutional investors. 10.6% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Zymergen and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Zymergen||$16.74 million||-$361.79 million||-0.18|
|Zymergen Competitors||$2.79 billion||$101.13 million||21.75|
Zymergen’s competitors have higher revenue and earnings than Zymergen. Zymergen is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Zymergen competitors beat Zymergen on 11 of the 12 factors compared.
About Zymergen (Get Rating)
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.
Receive News & Ratings for Zymergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymergen and related companies with MarketBeat.com's FREE daily email newsletter.